SNS-032
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


SNS-032
Description :
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC50s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect[1].CAS Number :
[345627-80-7]Product Name Alternative :
BMS-387032UNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
Apoptosis; CDKType :
Reference compoundRelated Pathways :
Apoptosis; Cell Cycle/DNA DamageApplications :
Cancer-Kinase/proteaseField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/SNS-032.htmlPurity :
99.91Solubility :
DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)Smiles :
CC(C)(C1=CN=C(CSC2=CN=C(NC(C3CCNCC3)=O)S2)O1)CMolecular Formula :
C17H24N4O2S2Molecular Weight :
380.53Precautions :
H302, H315, H319, H335References & Citations :
[1]Chen R, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113 (19) :4637-45.|[2]Ali MA, et al. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia. 2007 May;9 (5) :370-81.|[3]Conroy A, et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009 Sep;64 (4) :723-32.|[4]Wu Y, et al. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.Clin Cancer Res. 2012 Apr 1;18 (7) :1966-78. Epub 2012 Mar 23.|[5]Walsby E, et al. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells. Leukemia. 2011 Mar;25 (3) :411-9. Epub 2011 Jan 7.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
Phase 1Isoform :
CDK1; CDK2; CDK4; CDK7; CDK9

